医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2014年
10期
1936-1938
,共3页
刘鹏%赵志涛%张立科%田延锋%赵增仁
劉鵬%趙誌濤%張立科%田延鋒%趙增仁
류붕%조지도%장립과%전연봉%조증인
结直肠肿瘤/治疗%胃肠道间质肿瘤/治疗%哌嗪类/治疗应用%嘧啶类/治疗应用%随访研究%预后
結直腸腫瘤/治療%胃腸道間質腫瘤/治療%哌嗪類/治療應用%嘧啶類/治療應用%隨訪研究%預後
결직장종류/치료%위장도간질종류/치료%고진류/치료응용%밀정류/치료응용%수방연구%예후
Colorectal Neoplasms/TH%Gastrointestinal Stromal Tumors/TH%Piperazines/TU%Py-rimidines/TU%Follow -Up Studies%Prognosis
【目的】分析结直肠间质瘤的临床特点及其影响预后的因素。【方法】回顾性分析52例结直肠间质瘤患者的临床资料并进行随访。【结果】52例患者结直肠间质瘤发生于结肠23例(44.2%),直肠29例(55.8%);主要表现为腹部不适(48.1%),大便习惯改变或便血(34.6%)。41例手术完整切除;有效随访50例,免疫组化表型CD117阳性率为96.0%(48/50),中位生存时间为70个月,1、3、5、7、10年生存率分别为90%、77.5%、58.9%、43.2%、17.6%。年龄、手术切除的完整性、危险程度分级及伊马替尼治疗是影响预后的因素( P<0.05)。【结论】手术完整切除是结直肠间质瘤主要治疗手段,配合伊马替尼治疗效果显著;伊马替尼辅助治疗是影响患者预后的因素。
【目的】分析結直腸間質瘤的臨床特點及其影響預後的因素。【方法】迴顧性分析52例結直腸間質瘤患者的臨床資料併進行隨訪。【結果】52例患者結直腸間質瘤髮生于結腸23例(44.2%),直腸29例(55.8%);主要錶現為腹部不適(48.1%),大便習慣改變或便血(34.6%)。41例手術完整切除;有效隨訪50例,免疫組化錶型CD117暘性率為96.0%(48/50),中位生存時間為70箇月,1、3、5、7、10年生存率分彆為90%、77.5%、58.9%、43.2%、17.6%。年齡、手術切除的完整性、危險程度分級及伊馬替尼治療是影響預後的因素( P<0.05)。【結論】手術完整切除是結直腸間質瘤主要治療手段,配閤伊馬替尼治療效果顯著;伊馬替尼輔助治療是影響患者預後的因素。
【목적】분석결직장간질류적림상특점급기영향예후적인소。【방법】회고성분석52례결직장간질류환자적림상자료병진행수방。【결과】52례환자결직장간질류발생우결장23례(44.2%),직장29례(55.8%);주요표현위복부불괄(48.1%),대편습관개변혹편혈(34.6%)。41례수술완정절제;유효수방50례,면역조화표형CD117양성솔위96.0%(48/50),중위생존시간위70개월,1、3、5、7、10년생존솔분별위90%、77.5%、58.9%、43.2%、17.6%。년령、수술절제적완정성、위험정도분급급이마체니치료시영향예후적인소( P<0.05)。【결론】수술완정절제시결직장간질류주요치료수단,배합이마체니치료효과현저;이마체니보조치료시영향환자예후적인소。
[Objective] To analyze clinical characteristics and prognostic factors of colorectal interstitial tumor. [Methods] Clinical data of 52 patients with colorectal interstitial tumor were analyzed retrospectively. All patients were followed up. [Results] There were 23 cases of colorectal interstitial tumor located in colon (44. 2% ) and 29 cases located in rectum (55. 8% ). The main manifestations were abdominal discomfort (48. 1% ) and the change of defecation or bloody stool (34. 6% ). Tumors were completely removed in 41 cases. The effective follow‐up was performed in 50 patients. The positive rate of immunohistochemical phenotype CD118 was 96. 0% (48/50). The median survival time was 70. 0 months. The overall 1, 3, 5, 7 and 10‐year survival rates were 90. 0%, 77. 5%, 58. 9%, 43. 2% and 17. 6%, respectively. The age, integrity of tumor resection, risk level classification and ima‐tinib treatment were the prognostic factors ( P <0. 05). [Conclusion] The complete surgical resection is the main method for the treatment of colorectal interstitial tumor. The surgery combined with imatinib can achieve signifi‐cant efficacy. The adjuvant treatment with imatinib is the prognostic factor.